PD-L1 Inhibitor-Induced Thyroiditis is Associated with Better Overall Survival in Cancer Patients.
Thyroid immune-related adverse events (IRAEs) have been reported more frequently with programmed cell death protein-1 (PD-1) inhibitors as compared to cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, but there is limited data describing endocrinopathies from programmed cell death protein-ligand 1 (PD-L1) inhibitors. This study characterizes thyroid IRAEs in cancer patients treated with PD-L1 inhibitors, and examines the impact on overall survival. This is a retrospective cohort study of cancer patients treated with atezolizumab and avelumab at Mayo Clinic, Rochester, Minnesota, from 6/1/2016 - 1/30/2018, and followed for a median of 10.1 months. Thyroid IRAEs were characterized as new onset hypothyroidism, thyrotoxicosis and worsening of preexisting hypothyroidism. Of 91 patients treated with a PD-L1 inhibitor, 19 (21%) developed new onset thyroid dysfunction, of which 14 presented with hypothyroidism and 5 with thyrotoxicosis (3 progressed to hypothyroidism, 2 returned to euthyroidism), and 4 (4%) had worsening of preexisting hypothyroidism. Thyroid IRAEs occurred after a median of 2 doses (6 weeks), 48% required thyroid hormone replacement, and none required steroids or discontinuation of immunotherapy. 2/4 patients with thyroid peroxidase (TPO) antibody >9 IU/mL at baseline developed thyroid IRAEs. Median TPO antibody titer was not different between those with and without thyroid IRAEs but was higher in those with overt as compared to subclinical hypothyroidism (5 vs. 0.3 IU/mL, p=0.003) and those prescribed thyroid hormone replacement as compared to observation (5.5 vs. 0.3, p=0.008). Diffusely increased thyroid 18-fluorodeoxyglucose (<sup>18</sup>FDG) uptake on positron emission tomography (PET) scan occurred in 71% with thyroid IRAE as compared to 6% without (p=0.001). Patients that developed thyroid IRAEs had longer overall survival (p=0.027), and lower mortality (hazard ratio 0.49; 95% CI 0.25 to 0.99; p=0.034) after adjusting for potential confounders. PD-L1 inhibitors lead to immune mediated thyroiditis, the most frequent endocrine IRAE. In most cases, management is supportive without requiring steroids or discontinuation of immunotherapy. Diffusely increased thyroid <sup>18</sup>FDG uptake on PET scan may predict the occurrence of thyroiditis, whereas TPO antibodies may help identify its severity. Thyroiditis may be a biomarker for anti-tumor immune response, highlighting the need to further characterize its underlying mechanism.